Citius Oncology (CTOR) Earnings Analysis

Citius Oncology (CTOR) next reports earnings on 2026-08-18, consensus EPS -0.04 USD. Last quarter (2026-05-15) it missed with EPS -0.27 USD vs -0.01 USD est (-2600%). It has beaten estimates in 2/6 recent quarters (33%). Trailing P/E -1.22.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does CTOR next report earnings?

Next earnings date2026-08-18
Consensus EPS estimate-0.04 USD
Revenue estimate0.01B

CTOR earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-15-0.27 USD-0.01 USD-2600%Miss
2026-02-13-0.06 USD-0.04 USD-50%Miss
2025-12-23-0.06 USD-0.06 USD0%Beat
2025-05-14-0.11 USD-0.09 USD-22.2%Miss
2025-02-14-0.09 USD-0.06 USD-50%Miss
2024-12-27-0.07174 USD-0.08 USD+10.3%Beat

Beat rate: 2/6 (33%) over reported quarters with consensus data.

CTOR valuation and analyst view

Trailing P/E-1.22
Trailing EPS-0.42499 USD
Price / book1.63
Dividend yield0.00%
Market cap0.06B
Analyst consensusBuy (2 buy / 0 hold / 0 sell)
Avg price target6 USD

Related research pages

Frequently asked questions

When is Citius Oncology (CTOR)'s next earnings date?

Citius Oncology is next scheduled to report on 2026-08-18, with a consensus EPS estimate of -0.04 USD and revenue estimate of 0.01B.

Did CTOR beat earnings last quarter?

In its 2026-05-15 report, CTOR posted EPS of -0.27 USD versus a -0.01 USD estimate — a miss of 2600%.

What is CTOR's earnings track record?

Over the last 6 reported quarters with consensus data, CTOR beat estimates 2 times (33%).

What is CTOR's current P/E ratio and EPS?

CTOR trades at a trailing P/E of -1.22 on trailing EPS of -0.42498814622470105 USD.

What do analysts rate CTOR?

Analyst consensus is "Buy" across 2 ratings (0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 6 USD.